A week after microcap Tokai saw its shares plummet after the failure of its key Phase III prostate cancer candidate galeterone, the biotech has unsurprisingly…

With a confidentiality agreement in place, Sanofi says it is ready to move quickly to wrap up its pursuit of Medivation.

AstraZeneca has dropped 6 drug programs from its pipeline--with almost all the early-stage candidates being axed from its MedImmune biologics arms--in what is…

Unlikely IPO candidate Kadmon made it out in a tough IPO market amid swirling criticisms of its rather infamous current and former management, namely the…

It’s been a torrid first half for Aegerion Pharmaceuticals that began the year with a 25% cut to its staff, but the biotech is swinging the ax again--this time…

Gene therapy player Audentes Therapeutics priced at the midpoint of its IPO range, raising $75 million, and then proceeded to move up about 10% in early…

Poxel has hit pause on its plan to file for an IPO on Nasdaq, opting instead to use its Euronext listing to generate €26.5 million to advance its Type 2…

Ionis Pharmaceuticals has sold the rights to its early-stage GI autoimmune disease candidate IONIS-JBI1-2.5Rx to Janssen as the company announces strong growth…